149
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis

, , ORCID Icon, , , , , , , , & show all
Pages 67-71 | Received 26 Jun 2020, Accepted 11 Aug 2020, Published online: 07 Sep 2020

References

  • Smolen J-S, Daniel A, McInnes I-B. Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
  • Shekhani M-T, Forde T-S, Adilbayeva A, et al. Collagen triple helix repeat containing 1 is a new promigratory marker of arthritic pannus. Arthritis Res Ther. 2016;18:171.
  • Kilani-Ruhangiz T, Maksymowych-Walter P, Aitken A, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007;34:1650–1657.
  • Maksymowych W-P, Désirée VDH, Cornelia-F A, et al. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res. Ther. 2014;16:1–11.
  • Zhu J, Liuyan N, Xiaoyong L, et al. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? Clin Chem Lab Med. 2019;57:1668–1679.
  • Esalatmanesh K, Raika J, Arsia J, et al. Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis. Rheumatol Int. 2012;32:3799–3805.
  • Aletaha D, Tuhina N, Alan-J S, et al. Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheumatism. 2010;62:2569–2581.
  • Tasliyurt T, Bunyamin K, Suheyla-Uzun K, et al. The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern turkey. Rheumatol Int. 2013;33:939–942.
  • Myngbay A, Askhat M, Yergali B, et al. CTHRC1: a new candidate biomarker for improved rheumatoid arthritis diagnosis. Front Immunol. 2019;10:1–12.
  • Zeng T, Tan L. 14-3-3eta protein: a promising biomarker for rheumatoid arthritis. Biomark Med. 2018;12:917–925.
  • Xun G, Sheng-Qian X, Ying W, et al. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol. 2017;36:2581–2587.
  • Alessandri C, Agmon-Levin N, Conti F, et al. Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features. Immunol Res. 2017;65:524–531.
  • Zhu T, Feng L. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients. Int J Rheum Dis. 2013;16:157–161.
  • El-Sherif WT, Nigm DA, Abd-Elsamea MH, et al. Evaluation of serum protein 14-3-3η (Eta) as a novel biomarker for rheumatoid arthritis. Egypt J Immunol. 2019;26:163–175.
  • Derksen V-F-A-M, Huizinga T-W-J, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017;39:437–446.
  • Sun P, Wang W, Chen L, et al. Diagnostic value of autoantibodies combined detection for rheumatoid arthritis. J Clin Lab Anal. 2017;31:1–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.